Citation
Rakib, Ahmed, et al. "Immunoinformatics-guided Design of an Epitope-based Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein." Computers in Biology and Medicine, vol. 124, 2020, p. 103967.
Rakib A, Sami SA, Mimi NJ, et al. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Comput Biol Med. 2020;124:103967.
Rakib, A., Sami, S. A., Mimi, N. J., Chowdhury, M. M., Eva, T. A., Nainu, F., Paul, A., Shahriar, A., Tareq, A. M., Emon, N. U., Chakraborty, S., Shil, S., Mily, S. J., Ben Hadda, T., Almalki, F. A., & Emran, T. B. (2020). Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Computers in Biology and Medicine, 124, 103967. https://doi.org/10.1016/j.compbiomed.2020.103967
Rakib A, et al. Immunoinformatics-guided Design of an Epitope-based Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein. Comput Biol Med. 2020;124:103967. PubMed PMID: 32828069.
TY - JOUR
T1 - Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.
AU - Rakib,Ahmed,
AU - Sami,Saad Ahmed,
AU - Mimi,Nusrat Jahan,
AU - Chowdhury,Md Mustafiz,
AU - Eva,Taslima Akter,
AU - Nainu,Firzan,
AU - Paul,Arkajyoti,
AU - Shahriar,Asif,
AU - Tareq,Abu Montakim,
AU - Emon,Nazim Uddin,
AU - Chakraborty,Sajal,
AU - Shil,Sagar,
AU - Mily,Sabrina Jahan,
AU - Ben Hadda,Taibi,
AU - Almalki,Faisal A,
AU - Emran,Talha Bin,
Y1 - 2020/08/13/
PY - 2020/05/28/received
PY - 2020/08/08/revised
PY - 2020/08/08/accepted
PY - 2020/8/23/pubmed
PY - 2020/9/25/medline
PY - 2020/8/23/entrez
KW - COVID-19
KW - Epitope
KW - Immunoinformatics
KW - SARS-CoV-2
KW - Spike glycoprotein
SP - 103967
EP - 103967
JF - Computers in biology and medicine
JO - Comput Biol Med
VL - 124
N2 - AIMS: With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells. MAIN METHODS: Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells. KEY FINDINGS: We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the world's population. Furthermore, we predicted CD4+ T-cell epitopes and B-cell epitopes. SIGNIFICANCE: Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes.
SN - 1879-0534
UR - https://www.unboundmedicine.com/medline/citation/32828069/Immunoinformatics_guided_design_of_an_epitope_based_vaccine_against_severe_acute_respiratory_syndrome_coronavirus_2_spike_glycoprotein_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010-4825(20)30300-0
DB - PRIME
DP - Unbound Medicine
ER -